Role of Antigen Selectivity in Autoimmune Responses to the Ku (p70/p80) Antigen

Westley H. Reeves, Zev M. Sthoeger, and Robert G. Lahita*
The Rockefeller University, New York 10021; *Cornell University Medical Center, New York 10021

Abstract

Levels of anti–Ku (p70/p80) antibodies were measured longitudinally in sera from four individuals with systemic lupus erythematosus or related disorders. Antibodies to the native Ku antigen (p70/p80 complex) varied over a range of up to 577-fold. Large fluctuations were also observed in the levels of autoantibodies to several distinct epitopes of the Ku (p70/p80) antigen. Levels of these individual autoantibody populations generally paralleled one another, suggesting that they are coordinately regulated. A similar pattern of anti–DNA antibody fluctuation was seen in some sera. To examine the possibility that these autoantibodies were generated by polyclonal B cell activation, the levels of anti–Ku (p70/p80) and anti–DNA antibodies were compared to the levels of antibodies to *Escherichia coli* proteins, tetanus toxoid, and bovine insulin, transferrin, cytochrome c, serum albumin, and thyroglobulin. In sera from the same individual, anti–Ku (p70/p80) antibodies were sometimes produced in the complete absence of polyclonal activation, and at other times were accompanied by increased polyclonal activation. Anti–DNA antibody levels more closely paralleled the level of polyclonal activation than did the anti–Ku (p70/p80) levels. These studies suggest that anti–Ku (p70/p80) antibodies are generated by an antigen-selective mechanism, but that polyclonal activation frequently, although not invariably, accompanies autoantibody production. This observation is consistent with the possibility that polyclonal activation might be secondary to autoantibody production.

Introduction

Antinuclear antibodies are one of the most consistent findings in systemic lupus erythematosus (SLE) 1 (1). The origin of these autoantibodies, and the explanation of their selectivity for nuclear antigens remain obscure. Although certain healthy individuals produce small amounts of autoantibodies similar to those in sera of individuals with SLE or related diseases (2), overproduction of the same autoantibodies correlates strongly with particular subsets of autoimmune disease (1, 3). Whether overproduction of these autoantibodies in disease is the result of non-specific polyclonal B cell activation (4, 5), or of a more selective, antigen-driven mechanism involving somatic mutation of immunoglobulin genes (6–9), remains controversial.

In these studies, we assessed the roles of polyclonal activation and antigen-selection in the generation of autoantibodies to the Ku (p70/p80) antigen, a macromolecular complex consisting of ~ 70,000- and ~ 80,000-dalton proteins which bind to DNA (10–14). Extremely large amounts of anti–Ku (p70/p80) autoantibodies are found in sera of certain Americans with SLE, mixed connective tissue disease (MCTD), and progressive systemic sclerosis (scleroderma, PSS) (10), and in Japanese with PSS-polymyositis overlap syndrome (11). The diversity of anti–Ku (p70/p80) antibodies and their fluctuation patterns over time observed in the present studies favor a selective, antigen-driven mechanism for their overproduction and raise the possibility that polyclonal activation might occur secondarily.

Method

Patients. Sera were obtained from four female patients diagnosed and treated at The Rockefeller University Hospital. Patients CK and MG had SLE, as defined by the American Rheumatism Association criteria (15), patient JM had MCTD (16), and patient JK had PSS (17).

ELISA for anti–Ku (p70/p80) antibodies. Anti–Ku (p70/p80) antibodies were quantitated by ELISA (10). Microtiter plates were coated with monoclonal anti–Ku (p70/p80) antibody 162-11, and antigen from human K562 cell extract was bound. DNA was dissociated from the immobilized antigen by washing with 0.5 M NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA (18). Diluted human sera were added to the wells for 90 min at 22°C, followed by peroxidase-conjugated goat anti–human immunoglobulin antibodies (λ and light chain specificities, from Tago Inc., Burlingame, CA) for an additional 90 min. Absorbance (A) was read at 490 nm 1 h after adding substrate. The relative amounts of anti–p70/p80 antibodies in individual serum samples from the same patient were determined as follows: serial fivefold dilutions from 1:50 to 1:3,906,250 were tested by ELISA, and A490 was plotted as a function of serum dilution. The log, difference in antibody levels was determined from the titration curves of the individual sera.

Levels of other types of antibodies. Levels of anti–double-stranded (ds) DNA antibodies were determined by RIA (19) or ELISA (20). Relative amounts of anti–dsDNA antibodies in individual sera of the same patient were determined from titration curves in ELISA as described above for anti–Ku (p70/p80) antibodies. Anti–tetanus toxoid antibodies were measured by ELISA (21), as were levels of antibodies to the following bovine proteins: insulin, transferrin, cytochrome c, serum albumin, and thyroglobulin (all from Sigma Chemical Company, St. Louis, MO). Each antigen was allowed to bind to microtiter plates (Nunc Immunoplate I, from VWR Scientific, San Francisco, CA) at a concentration of 10 µg/ml for 12 h at 4°C, before washing, blocking, and incubating the wells for 3 h with diluted antiserum (22). Peroxidase-conjugated goat anti–human immunoglobulin antibodies (λ and light chain-specific) were then added as described above, followed by addition of substrate.

Competition ELISA. Relative amounts of serum autoantibodies to different epitopes of the native Ku (p70/p80) antigen complex were determined by competition ELISA (10) using two murine monoclonal anti–Ku (p70/p80) antibodies reactive with distinct epitopes. Micro-
titer plates were coated with one monoclonal antibody, and antigen was bound to the coating antibody. The binding of the other monoclonal antibody (labeled with alkaline phosphatase) to the immobilized antigen was then measured in the presence of serial dilutions of serum and the dilution producing 50% inhibition of binding was taken as a measure of the amount of competing antibody present in the serum.

**Immunoblotting.** The specificities of human autoimmune sera were analyzed by immunoblotting using p70 and p80 proteins that were affinity-purified from K562 cell extract onto monoclonal antibody 162-11-coated protein A-Sepharose beads (Pharmacia Fine Chemicals, Piscataway, NJ) (10). The washed beads were eluted by boiling 3 min in SDS sample buffer, analyzed on 10% preparative SDS-polyacrylamide gels (23), and transferred to nitrocellulose (BA-85, Schleicher & Schuell, Inc., Keene, NH) (24). The blots were blocked in 150 mM NaCl, 50 mM Tris pH 7.5, 0.02% NaN3 containing 1% bovine hemoglobin, incubated with serum (1:500 in blocking solution for 3–12 h), washed, and incubated 3 h with [125I]-protein A (New England Nuclear, Boston, MA; 103 dpm/ml). After exposure to X-ray film, individual protein bands of equal width were cut from the nitrocellulose, and bound radioactivity was quantitated by gamma counting. Standard curves of counts per minute versus serum concentration were generated for each antigen.

**p70 fusion protein.** The 70.77 fusion protein consists of the amino-terminal ~110 kD of β-galactosidase linked to the carboxy-terminal 189 amino acids of p70 (25). Production of the fusion protein by *Escherichia coli* lysogenic for the recombinant lambda phage was induced by addition of isopropyl β-D-thiogalactopyranoside (IPTG) to bacterial cultures (26). Lysates from lysogenized *E. coli* Y1089, or control Y1089 cells were subjected to SDS-PAGE, followed by immunoblotting as described above.

**Results**

Examination of serial serum samples from an individual with SLE revealed striking differences in the levels of autoantibodies to the native p70/p80 (Ku) antigen over time (Fig. 1). These antibodies were present in only small quantities in 5-79 (Fig. 1, indicated by *). The amount of anti–Ku (p70/p80) antibodies in 5-79 serum was arbitrarily assigned a value of 1 U, and the amounts of anti–Ku (p70/p80) antibodies in subsequent sera were compared to this standard serum. The anti–Ku (p70/p80) antibodies had increased 15.4-fold by 1-80 (Fig. 1, point a), 25-fold by 12-80 (point b), 106-fold by 1-84 (point c), and 577-fold by 7-84 (point d), compared to the reference serum. Between these peaks (a–d) of anti–Ku (p70/p80) autoantibodies, the levels declined considerably, suggesting that the autoantibodies were generated intermittently. To investigate the mechanism by which these antibodies were generated, we first examined whether the anti–Ku (p70/p80) autoantibodies in CK sera were monoclonal or multiclonal (Fig. 2, Table I). Immunoblotting of purified p70 and p80 proteins (Fig. 2 A) indicated that the autoantibodies were highly specific for p70 until 4-80, when anti–p80 autoantibodies appeared for the first time (Fig. 2 A, lane 10). Thus, after 4-80, the autoantibodies were reactive with at least two epitopes, one on denatured p70, and the other on denatured p80. Purification of the individual autoantibody populations by elution from immunoblots (27) confirmed that the anti-p70 antibodies were unreactive with p80, and vice versa (data not shown). Autoantibodies to the 70.77 fusion protein produced a fluctuation pattern similar to that of antibodies to intact p70 on immunoblots (Fig. 2 B). When these autoantibody populations were quantitated (Fig. 3), similarities between the levels of autoantibodies to p80 (Fig. 3 A), p70 (Fig. 3 B), and the 70.77 fusion protein (Fig. 3 C) were obvious. For each peak of anti–Ku (p70/p80) antibodies (points a–d, Fig. 1), a corresponding peak of p70, p80, and 70.77 fusion protein antibodies was observed. However, the relative magnitudes of the peaks varied, depending on which population of autoantibodies was measured (compare Fig. 3, A and B). Autoantibodies to two distinct epitopes of the native Ku (p70/p80) complex were also measured in serial sera from patient CK (Table I) by competition ELISA using native antigen. The autoantibodies measured in these assays are reactive with epitopes of native Ku (p70/p80), but not the denatured antigen. Levels of antibodies to native Ku (p70/p80) epitopes paralleled the levels of antibodies to denatured p70 and p80.

Autoantibodies to another antigen, dsDNA, displayed a similar pattern of fluctuation (Fig. 3 D), although some differences were noted. In particular, anti–dsDNA antibodies frequently peaked slightly after the peaks of anti–p70, anti–p80, and anti–70.77 antibodies (Fig. 3, A–D, points a and b). The similarities in the fluctuation patterns of anti–Ku (p70/p80) and anti–dsDNA antibodies suggested that these distinct populations of autoantibodies are coordinate regulated. We therefore investigated the possibility that the coordinate regulation of the different autoantibody populations might be due to intermittent polyclonal B cell activation.

When antibodies to two *E. coli* proteins, of *M*5, ~56 and ~86 kD were measured, some similarities with the patterns of variability of anti–Ku (p70/p80) and anti–DNA antibodies were seen (Fig. 3, E and F). At point a (Fig. 3), a peak of autoantibody levels was accompanied by a peak of antibodies to both *E. coli* proteins. However, at point c the peak of autoantibodies was accompanied by a peak of antibodies to the 56-kD, but not the 86-kD *E. coli* protein, and at points b and d, there was little or no increase in the levels of either *E. coli* protein. Like anti–dsDNA antibodies, the peak of anti–*E. coli* antibodies sometimes occurred slightly later than the peak of anti–Ku (p70/p80) antibodies. The relationship between autoantibody production and polyclonal activation was further investigated by comparing levels of anti–Ku (p70/p80) and anti–dsDNA autoantibodies with levels of antibodies to five bovine proteins (insulin, transferrin, cytochrome c, serum albumin, and thyroglobulin), and tetanus toxin in sera from four individuals (Tables I–IV).
Maximum titers of anti-Ku (p70/p80) antibodies in the four individuals' sera were as follows: CK, > 1:3,906,250; JM, 1:3,906,250; MG, > 1:3,906,250, and JK, 1:156,250. Antibodies to the exogenous proteins were present in low levels in these autoimmune sera, and in the absence of immunization, their levels should be reflective of the general state of polyclonal B cell hyperactivity. Because of the low levels of these antibodies, precise quantitation of their levels by comparing titration curves was not possible, but the absorbance at 490 nm produced by a 1:50 serum dilution reproducibly gave a qualitative, if only semiquantitative, measure of the level of polyclonal activation. In serial CK sera (Table I), the level of polyclonal activation decreased from 6-80 to 12-80, as indicated by a decrease in the levels of antibodies to insulin, transferrin, cytochrome c, bovine serum albumin, thyroglobulin, and tetanus toxoid. At the same time, anti-Ku (p70/p80) autoantibodies increased from 5.5% to 71.4%. Thus, between these two points in time, production of anti-Ku (p70/p80) autoantibodies was completely dissociated from the level of polyclonal activation. However, between 3-84 and 7-84, an increase in anti-Ku (p70/p80) antibodies was accompanied by a parallel increase in the level of polyclonal activation. These results, as well as the findings with E. coli proteins, suggest that autoantibody generation is sometimes independent of the production of antibodies to exogenous antigens, and is sometimes accompanied by evidence of polyclonal activation. In general, the levels of anti–dsDNA antibodies correlated better than the levels of anti-Ku (p70/p80) antibodies with the level of polyclonal activation.

The levels of anti-Ku (p70/p80), and anti–dsDNA autoantibodies were compared with the levels of antibodies to exogenous antigens in serial sera from three other patients (Tables II–IV), with results similar to those illustrated by sera from patient CK (Table I). For example, in sera from patient JM, a striking increase in polyclonal activation was observed between 3-85 and 11-86 (Table II), while at the same time, anti-Ku (p70/p80) antibodies decreased significantly. The anti-DNA antibody levels paralleled the level of polyclonal activation, rather than the anti-Ku (p70/p80) autoantibody levels, further reinforcing the impression that anti–DNA autoantibody production is more closely linked to polyclonal activation than is the production of anti-Ku (p70/p80) antibodies. Similar results were obtained with sera from the other two individuals. Notably, the level of polyclonal activation in sera from patient JK, an individual with PSS, was significantly less than the levels of polyclonal activation detected in sera from the other patients, who had SLE (CK, MG) or MCTD (JM). In addition, the anti-Ku (p70/p80) autoantibody levels displayed considerably less variability in sera from patient JK than was observed in the other sera.

**Discussion**

Polyclonal activation of B cells has been proposed as a mechanism for generating autoantibodies in murine and human lupus (4, 5). Alternatively, autoantibodies might arise by antigenic stimulation and somatic mutation of specific B cells (6–9). In the present studies, specific autoantibody levels were compared over time to levels of antibodies to exogenous antigens to assess the role of random, polyclonal activation versus that of antigen selection (28–31) in the production of autoantibodies in human SLE.
Figure 3. Levels of antibodies to components of the Ku (p70/p80) complex and to E. coli proteins in serial CK sera. The same sera analyzed in Figs. 1 and 2 were examined for levels of antibodies to the following: (A) denatured p80, (B) denatured p70, (C) 70.77 fusion protein (containing a major autoepitope of p70), (D) double-stranded DNA, (E) a 56-kD E. coli protein, and (F) a 86-kD E. coli protein. Antibody levels were measured by quantitative immunoblotting (A–C, E and F) or by RIA (D).

We observed parallel fluctuations in the levels of autoantibodies to several independent epitopes of the Ku (p70/p80) autoantigen, including epitopes of denatured p70 and p80, as well as two distinct epitopes of the native Ku (p70/p80) complex. Anti-DNA antibodies frequently displayed parallel fluctuations, but the peak levels of these antibodies often occurred several weeks after the peaks of anti-Ku (p70/p80) autoantibodies. Surprisingly, peaks of anti-Ku (p70/p80) autoantibodies were sometimes accompanied by peaks of polyclonal activation as determined by measuring levels of several exogenous antigens, but at other times, were completely independent of the level of polyclonal activation. At times, anti-Ku (p70/p80) autoantibodies increased dramatically at the same time as a significant decrease in the level of polyclonal activation.

Table II. Antibody Levels in JM Sera

<table>
<thead>
<tr>
<th>Antigen</th>
<th>12-84</th>
<th>1-85</th>
<th>3-85</th>
<th>11-86</th>
<th>12-86</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin*</td>
<td>0.41</td>
<td>0.34</td>
<td>0.48</td>
<td>1.24</td>
<td>1.22</td>
</tr>
<tr>
<td>Transferrin*</td>
<td>0.23</td>
<td>0.21</td>
<td>0.22</td>
<td>0.61</td>
<td>0.67</td>
</tr>
<tr>
<td>Cytochrome c*</td>
<td>0.30</td>
<td>0.20</td>
<td>0.27</td>
<td>0.79</td>
<td>0.65</td>
</tr>
<tr>
<td>BSA*</td>
<td>0.21</td>
<td>0.21</td>
<td>0.23</td>
<td>0.61</td>
<td>0.56</td>
</tr>
<tr>
<td>Thyroglobulin*</td>
<td>0.33</td>
<td>0.30</td>
<td>0.37</td>
<td>0.61</td>
<td>0.65</td>
</tr>
<tr>
<td>Tetanus*</td>
<td>0.22</td>
<td>0.21</td>
<td>0.25</td>
<td>0.52</td>
<td>0.53</td>
</tr>
<tr>
<td>p70/p80t</td>
<td>100</td>
<td>32.3</td>
<td>38.5</td>
<td>14.5</td>
<td>12.3</td>
</tr>
<tr>
<td>dsDNA†</td>
<td>100</td>
<td>52.6</td>
<td>52.6</td>
<td>71.4</td>
<td>100</td>
</tr>
</tbody>
</table>

Table III. Antibody Levels in MG Sera

<table>
<thead>
<tr>
<th>Antigen</th>
<th>1-86</th>
<th>2-86</th>
<th>5-86</th>
<th>9-86</th>
<th>3-87</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin*</td>
<td>0.71</td>
<td>0.39</td>
<td>0.32</td>
<td>0.28</td>
<td>0.36</td>
</tr>
<tr>
<td>Transferrin*</td>
<td>0.20</td>
<td>0.40</td>
<td>0.29</td>
<td>0.20</td>
<td>0.24</td>
</tr>
<tr>
<td>Cytochrome c*</td>
<td>0.23</td>
<td>0.20</td>
<td>0.42</td>
<td>0.34</td>
<td>0.33</td>
</tr>
<tr>
<td>BSA*</td>
<td>0.19</td>
<td>0.16</td>
<td>0.39</td>
<td>0.35</td>
<td>0.30</td>
</tr>
<tr>
<td>Thyroglobulin*</td>
<td>0.29</td>
<td>0.22</td>
<td>0.40</td>
<td>0.24</td>
<td>0.33</td>
</tr>
<tr>
<td>Tetanus*</td>
<td>0.62</td>
<td>0.50</td>
<td>0.80</td>
<td>0.60</td>
<td>0.67</td>
</tr>
<tr>
<td>p70/p80t</td>
<td>100</td>
<td>10.5</td>
<td>20.0</td>
<td>38.5</td>
<td>14.5</td>
</tr>
<tr>
<td>dsDNA†</td>
<td>100</td>
<td>260</td>
<td>190</td>
<td>220</td>
<td>190</td>
</tr>
</tbody>
</table>

* A422, ELISA.
† Units, from ELISA titration curves. Reference serum = 100 U.
(Tables I–IV). The magnitude of the increases in anti–Ku (p70/p80) autoantibody levels also speaks strongly against the possibility that these autoantibodies were generated by polyclonal activation. For example, the 577-fold increase of anti–Ku (p70/p80) autoantibodies observed in patient CK serum (Fig. 1) could not have been accompanied by a comparable increase in total immunoglobulin levels. It should also be mentioned that the titers of anti–Ku (p70/p80) autoantibodies were considerably higher than the anti-DNA titers or the levels of antibodies to exogenous proteins (E. coli proteins, tetanus toxoid, and bovine proteins). Taken together, these observations suggest that the selective, intermittent activation of anti–Ku (p70/p80) autoantibody production may sometimes be accompanied (or followed) by secondary polyclonal activation. The reason that this is not always the case remains unclear.

Secondary polyclonal activation has been observed in several other situations. Resting B lymphocytes can be polyclonally activated to differentiate into antibody-secreting cells when cultured with MHC-compatible, antigen-specific T cells plus the antigen for which the T cells are specific (32). Similarly, immunization with tetanus toxoid can induce polyclonal activation (33), as can homologous immune complexes in vitro (34). Conceivably, the immune response to Ku (p70/p80) might lead to polyclonal activation through analogous mechanisms.

Another feature of the autoimmune response to Ku (p70/p80) is the tight linkage of anti–p70 antibody production with anti–p80 production, and to a lesser degree, with anti–DNA production (Fig. 2). Reactivity with each of these components consists primarily of IgG autoantibodies (our unpublished observation), suggesting the involvement of T cells. Since p70, p80, and DNA are components of the same macromolecular complex (10), it is tempting to speculate that the coordinate regulation of autoantibodies to these components might be related to a single population of Tc cells providing help for each of the autoantibody populations involved. There is precedent for such a mechanism in the production of antibodies to certain viruses (35, 36). For example, production of antibodies to the influenza virus hemagglutinin is supported equally well by Tc cells specific for the hemagglutinin, matrix protein, or nucleoprotein (35). Thus, in the case of a macromolecular complex, Tc cells appear to be capable of providing help for populations of B cells secreting antibodies reactive with epitopes that are not covalently linked to the T cell epitopes involved. This phenomenon might explain the linkage of anti–p70 and anti–p80 autoantibodies, and might also be responsible for the linked production of autoantibodies reactive with several different components of other macromolecular complexes (31).

In conclusion, our findings suggest that autoantibodies to different components of the p70/p80 (Ku) complex are coordinately regulated, and that their production is not due to polyclonal activation. However, a link with polyclonal activation is apparent. Further studies will be necessary to define the nature of this link between autoantibody production and polyclonal activation. The simplest, but not the only, explanation for this link is that polyclonal activation is secondary to the autoimmune response.

Acknowledgments

We thank Henrietta Carbonaro, Elena Kissin, and David Tirschwell for technical assistance, and Dr. Lloyd Mayer for providing sera from patient JK.

This work was supported by grant AR 01499 from the U.S. Public Health Service, and by a General Clinical Research Center grant (RR-00102) from the National Institutes of Health. Dr. Reeves is a recipient of an Arthritis Investigator Award from the Arthritis Foundation. Dr. Sthoegener is a fellow of the Lupus Foundation of New York.

References


